Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Argent Biopharma ( (AU:RGT) ) is now available.
Argent BioPharma has announced the issuance of 2,252,381 fully paid ordinary shares, which are exempt from certain disclosure requirements under the Corporations Act 2001. This move aligns with the company’s compliance with regulatory provisions, ensuring transparency and informed investor decisions. The issuance is part of Argent BioPharma’s strategy to advance its clinical programs and strengthen its market position in addressing urgent medical needs.
More about Argent Biopharma
Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company focused on developing nano-engineered medicines that address the balance between the nervous and immune systems. The company’s lead candidates, CannEpil® and CimetrA®, are designed to treat drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. Argent BioPharma utilizes proprietary delivery platforms to enhance drug efficacy and protection, with a focus on unmet needs in central nervous system and systemic inflammation.
Average Trading Volume: 98,425
Technical Sentiment Signal: Sell
Current Market Cap: A$8.68M
See more data about RGT stock on TipRanks’ Stock Analysis page.